Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders (2018 - 2026)

Amneal Pharmaceuticals' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $78.0 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 216.84% year-over-year to $78.0 million; the TTM figure through Mar 2026 stood at $181.3 million (up 459.27% YoY), while the FY2025 annual figure was $127.9 million, up 209.45% from the prior year.
• Net Income towards Common Stockholders was $78.0 million for Q1 2026 at Amneal Pharmaceuticals, up from $49.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $78.0 million in Q1 2026 to a low of -$120.8 million in Q2 2022.
• Historically, Net Income towards Common Stockholders has averaged -$4.8 million across 5 years, with a median of $9.7 million in 2023.
• Biggest YoY gain for Net Income towards Common Stockholders was 460.06% in 2023; the steepest drop was 2176.69% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$4.3 million in 2022, then sank by 2176.69% to -$98.6 million in 2023, then jumped by 78.97% to -$20.7 million in 2024, then soared by 339.0% to $49.6 million in 2025, then soared by 57.34% to $78.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $78.0 million (Q1 2026), $49.6 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.